Aquestive Therapeutics
A pharmaceutical company advancing medicines to solve patients’ problems with current standards of care.
A pharmaceutical company advancing medicines to solve patients’ problems with current standards of care.
Aquestive Therapeutics Analysis
Aquestive Therapeutics is a pharmaceutical company that aims to address the limitations of current standard treatments and enhance patients' quality of life. Established in 2004, the company focuses on developing orally administered products to deliver complex molecules, offering more convenient and non-invasive alternatives to existing therapies.
The company boasts five commercialized products in the U.S. market, with an additional four licensed products and one proprietary product, Sympazan® (clobazam) oral film, specifically designed for treating seizures associated with Lennox-Gastaut Syndrome. Moreover, Aquestive collaborates with other pharmaceutical firms to introduce new molecules via its proprietary technology, PharmFilm®.
Aquestive's last investment, totaling $75.00M, was in the form of Post-IPO Equity in March 19, 2024. Although the specific investors for this round are not disclosed, this investment showcases confidence in the company and its innovative approach to developing treatments for central nervous system diseases and severe allergic reactions like anaphylaxis.
This trajectory positions Aquestive Therapeutics as a compelling player in the pharmaceutical industry, with a focus on addressing unmet medical needs and striving for impactful advancements in patient care.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $75.00M | - | 19 Mar 2024 | |
| Post-IPO Debt | $45.00M | - | 02 Nov 2023 | |
| Post-IPO Equity | $8.50M | - | 08 Jun 2022 | |
| Post-IPO Equity | $40.00M | 1 |
|
13 Apr 2022 |
| Post-IPO Debt | $70.00M | 1 |
|
15 Jul 2019 |
No recent news or press coverage available for Aquestive Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
